Sodium Glucose Co-Transporter-2 inhibitors in patients with systemic sclerosis with or without heart failure
In this real-world analysis, SGLT2 inhibitors were associated with reduced mortality, stroke, and hospitalization in patients with systemic sclerosis, supporting their potential therapeutic role in this population.
Authors
- Soumya Chatterjee (ORCID: https://orcid.org/0000-0001-6017-5767)
- W.H. Wilson Tang (ORCID: https://orcid.org/0000-0002-8335-735X)
- Silvio Nunes Augusto (ORCID: https://orcid.org/0000-0002-7663-4902)
- David C. Kaelber (ORCID: https://orcid.org/0000-0001-7855-9515)
Institutions
- MetroHealth (US)
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- MetroHealth Medical Center (US)
Publication Details
- Journal
- The American Journal of Medicine
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1016/j.amjmed.2025.08.009
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- National Center for Advancing Translational Sciences